Indeed, proteomic studies revealed a significant enrichment in spliceosome components in CLL samples as compared to healthy volunteers, indicating the irrelevance of SF3B1 mutation status in splicing disruption [85]. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.